Summit Therapeutics, Inc.

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: US86627T1088

USD

17.94

2.4 (15.44%)

Mar 25

NAS

View all stocks in this country

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Rhythm Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc.

CymaBay Therapeutics, Inc.

Merus NV

AbCellera Biologics, Inc.

Maravai Lifesciences Holdings, Inc.

Arcus Biosciences, Inc.

Recursion Pharmaceuticals, Inc.

Summit Therapeutics, Inc.

Rocket Pharmaceuticals, Inc.

Why is Summit Therapeutics, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Summit Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Summit Therapeutics, Inc.

-11.36%

1.03

92.07%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-263.08%

EBIT to Interest (avg)

-47.20

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.04

Sales to Capital Employed (avg)

0.00

Tax Ratio

0.04%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

18.18%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

65.23

EV to EBIT

-13.16

EV to EBITDA

-13.16

EV to Capital Employed

-280.36

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-479.35%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -121.42 %

-13What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -274.13 MM

PRE-TAX PROFIT(Q)

At USD -231.79 MM has Fallen at -24.28%

NET PROFIT(Q)

At USD -231.79 MM has Fallen at -24.27%

Here's what is working for Summit Therapeutics, Inc.

Debt-Equity Ratio

Lowest at -121.42 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Summit Therapeutics, Inc.

Operating Cash Flow

Lowest at USD -274.13 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Pre-Tax Profit

At USD -231.79 MM has Fallen at -24.28%

over average net sales of the previous four periods of USD -186.5 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -231.79 MM has Fallen at -24.27%

over average net sales of the previous four periods of USD -186.52 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)